Core Insights - FG Nexus has implemented a $200 million common share buyback program to enhance shareholder value and increase net asset value (NAV) [2][4][6] - As of September 30, 2025, the company holds 50,778 ETH, $7.5 million in cash, and has total debt of $1.9 million, with total shareholders' equity at $231 million [3] - The company has repurchased 3.4 million common shares at an average price of approximately $3.45 per share since the buyback program commenced [4][6] Financial Metrics - Total ETH Holdings: 50,778 ETH as of September 30, 2025 [3] - Cash and Cash Equivalents: $7.5 million [3] - Total Debt: $1.9 million [3] - Total Shareholders' Equity: $231 million [3] - Book Value per Common Share: $5.80 [3] - As of November 19, 2025, the company holds 40,005 ETH and cash and USDC holdings of approximately $37 million, with total debt outstanding at $11.9 million [5] Share Buyback Program - The company commenced its share buyback program on October 23, 2025, borrowing approximately $10 million and selling 10,922 ETH to fund the repurchases [4] - The buyback has resulted in the repurchase of 8% of shares outstanding at a substantial discount to NAV [6] Strategic Focus - FG Nexus is focused on building a digital asset treasury and a platform for the tokenization of real-world assets [7] - The company plans to stake its ETH and implement additional yield strategies to enhance the yield on its treasury [7]

Core Insights - TTEC Holdings, Inc. is enhancing its presence in Latin America's banking and financial services sector, achieving significant results for global retail financial institutions [2][5] - The company leverages a skilled multilingual workforce in Latin America, particularly in Brazil, Colombia, and Mexico, to provide exceptional customer experience (CX) services [1][3] - TTEC's operations focus on combining technology with human talent, leading to improved customer satisfaction and operational efficiency [4][6] Company Performance - TTEC has been operational in Latin America for over a decade, with seven delivery centers across Mexico, Colombia, and Brazil [3] - A notable case involved a global money transfer service where TTEC's bilingual team in Colombia improved customer experience scores by 17%, achieved a 98% empathy score, and reduced average handle time by 15% [4] - The company has launched new engagements with multiple global retail banks, further solidifying its position as a preferred CX partner in the region [5] Talent and Culture - TTEC emphasizes attracting and retaining exceptional talent, resulting in industry-leading employee retention and satisfaction ratings [7] - The company is recognized as a Great Place to Work® in Mexico, Colombia, and Brazil, reflecting its commitment to employee development [7][8] - TTEC's investment in career building translates into higher performance and better customer outcomes, making it a strategic hub for financial services CX delivery [8]

Core Insights - MAIA Biotechnology has initiated patient enrollment in Romania for the Phase 2 THIO-101 Part C study, focusing on ateganosine as a treatment for advanced non-small cell lung cancer (NSCLC) patients [1][2] - The company aims to provide a promising alternative for NSCLC patients who have limited treatment options, with ateganosine showing a 38% response rate compared to current treatments with response rates of up to 6% [2][3] - The expansion of the study in Romania is part of MAIA's strategy to accelerate patient access to innovative therapies and pursue accelerated approval in the U.S. [2] Company Overview - MAIA Biotechnology is a clinical-stage biopharmaceutical company dedicated to developing targeted immunotherapies for cancer, with a focus on ateganosine as a potential first-in-class telomere-targeting agent for NSCLC [1][7] - The company received FDA's Fast Track Designation for ateganosine in July, which supports its goal of expedited development and review [2] Clinical Trial Details - The THIO-101 Phase 2 clinical trial is a multicenter, open-label study designed to evaluate the anti-tumor activity of ateganosine followed by PD-(L)1 inhibitors in advanced NSCLC patients who have previously shown resistance to other treatments [5][6] - The trial has two primary objectives: assessing the safety and tolerability of ateganosine and evaluating its clinical efficacy using Overall Response Rate (ORR) as the primary endpoint [5][6] Treatment Mechanism - Ateganosine works by inducing telomerase-dependent telomeric DNA modification, leading to selective cancer cell death and activation of immune responses [4] - The treatment aims to enhance and prolong immune response in patients with advanced NSCLC who have not responded to prior therapies [5]

Our press release for November 20th. Green Rain Energy Holdings announces the launch of 29 hotel-based EV charging projects across 16 states. This milestone accelerates the company’s mission to make clean transportation accessible nationwide. The deployment spans major hospitality brands including Marriott, Hilton and Sheraton, with locations in San Diego, Houston, Orlando, and New York. This approach supports local economies, reduces emissions, and strengthens tourism infrastructure. Follow us to le ...

Driven by a Vision to Deliver Smarter, Longer-Lasting Energy Solutions, Flux Power Integrates AI and Software Intelligence to Meet the Growing Demand for Adaptive, Data-Driven ElectrificationVISTA, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Flux Power Holdings, Inc. (NASDAQ: FLUX), a leading developer of advanced lithium-ion energy storage solutions and software-driven electrification for commercial and industrial equipment, today announced that the United States Patent and Trademark Office has issued U.S. P ...

Core Viewpoint - MarketWise, Inc. received an unsolicited non-binding acquisition proposal from Monument & Cathedral Holdings, LLC for $17.25 per share, contingent upon the termination of the Company's tax receivable agreement [1]. Group 1: Acquisition Proposal - The proposal involves acquiring all outstanding equity interests of MarketWise and Marketwise, LLC not owned by M&C [1]. - A Special Committee of the Board of Directors is reviewing the proposal with the assistance of financial and legal advisors [2]. Group 2: Company Overview - MarketWise is a leading multi-brand digital subscription services platform focused on providing premium financial research, software, education, and tools for self-directed investors [4]. - The company has over 25 years of operating history and serves millions of free and paid subscribers, offering its products through various digital platforms [5].

Tampa, Florida, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Draganfly Inc. (NASDAQ: DPRO) (CSE: DPRO) (FSE: 3U8A) (“Draganfly” or the “Company”), an award-winning, industry-leading drone solutions and systems developer, today announced that it has secured a strategically significant international military order for Commander 3XL drones. The order, placed through a recognized defense contractor, represents a significant milestone for Draganfly, reinforcing the Commander 3XL’s position as a trusted, multi-mission platf ...

LONDON, Nov. 20, 2025 (GLOBE NEWSWIRE) -- RedCloud Holdings plc (“RCT”) (“RedCloud” or “Company”) ​the RedAI intelligent trading platform used by Fast Moving Consumer Goods (FMCG) businesses, today announced a major update to its RedAI product, codenamed 'Genesis', with expected customer launch early 2026. To address the estimated $2 trillion1 global inventory gap caused by systemic inefficiencies across the $14Bn2 global FMCG supply chain, the RedAI trading platform already enables digital inventory exchan ...

- First closing of PIPE resulted in ~$1.79M in proceeds - - FDA BPD Type 2a meeting now scheduled for January 21, 2026 - IRVINE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE American: AEON), a biopharmaceutical company seeking accelerated and full-label U.S. market entry by developing ABP-450 (prabotulinumtoxinA) as a BOTOX (onabotulinumtoxinA) biosimilar, today announced the first closing of its previously announced private placement (“PIPE”). Additionally, ...

ROGERS, Ark., Nov. 20, 2025 (GLOBE NEWSWIRE) -- America’s Car-Mart, Inc. (NASDAQ: CRMT) today announced it will release fiscal 2026 second quarter financial results on Thursday, December 4, 2025, before the market opens. A webcast and conference call will be held that same day at 9:00 a.m. ET to review the Company’s results. Participants may access the conference call via webcast using this link: Webcast Link Here. To participate via telephone, please register in advance using this Registration Link. Upon r ...